Review ArticleReview
Open Access
Second-Line Systemic Therapy for Highly Aggressive Neuroendocrine Prostate Cancer
NAOHIRO FUJIMOTO, YUTO TSUBONUMA, YUJIRO NAGATA, AKINORI MINATO, IKKO TOMISAKI, KENICHI HARADA and HIROSHI MIYAMOTO
Anticancer Research September 2023, 43 (9) 3841-3847; DOI: https://doi.org/10.21873/anticanres.16571
NAOHIRO FUJIMOTO
1Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan;
YUTO TSUBONUMA
1Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan;
YUJIRO NAGATA
1Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan;
AKINORI MINATO
1Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan;
IKKO TOMISAKI
1Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan;
KENICHI HARADA
1Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan;
HIROSHI MIYAMOTO
2Department of Pathology & Laboratory of Medicine and Urology, University of Rochester Medical Center, Rochester, NY, U.S.A.
In this issue
Second-Line Systemic Therapy for Highly Aggressive Neuroendocrine Prostate Cancer
NAOHIRO FUJIMOTO, YUTO TSUBONUMA, YUJIRO NAGATA, AKINORI MINATO, IKKO TOMISAKI, KENICHI HARADA, HIROSHI MIYAMOTO
Anticancer Research Sep 2023, 43 (9) 3841-3847; DOI: 10.21873/anticanres.16571
Jump to section
Related Articles
- No related articles found.
Cited By...
- No citing articles found.